Your browser is no longer supported. Please, upgrade your browser.
Settings
VERA [NASD]
Vera Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.69 Insider Own0.90% Shs Outstand20.97M Perf Week6.99%
Market Cap359.47M Forward P/E- EPS next Y-2.90 Insider Trans0.00% Shs Float20.77M Perf Month3.87%
Income-14.20M PEG- EPS next Q-0.59 Inst Own80.80% Short Float0.53% Perf Quarter-1.02%
Sales- P/S- EPS this Y-350.60% Inst Trans1.64% Short Ratio1.61 Perf Half Y-
Book/sh4.39 P/B3.97 EPS next Y0.70% ROA- Target Price26.00 Perf Year-
Cash/sh4.45 P/C3.92 EPS next 5Y- ROE- 52W Range11.30 - 33.45 Perf YTD51.74%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-47.83% Beta-
Dividend %- Quick Ratio25.40 Sales past 5Y- Gross Margin- 52W Low54.42% ATR2.18
Employees13 Current Ratio25.40 Sales Q/Q- Oper. Margin- RSI (14)50.38 Volatility7.94% 11.66%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.19 Prev Close17.09
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume68.99K Price17.45
Recom1.70 SMA205.14% SMA50-5.60% SMA2002.61% Volume13,286 Change2.11%
Oct-13-21 07:30AM  
Sep-09-21 07:30AM  
Sep-07-21 04:58AM  
Aug-18-21 02:45PM  
Aug-16-21 07:30AM  
Jul-14-21 07:30AM  
Jun-24-21 07:15AM  
Jun-15-21 11:37AM  
May-27-21 04:05PM  
May-14-21 03:40PM  
May-13-21 08:52PM  
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.